Advertisement

Topics

UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary

08:58 EDT 2 Aug 2017 | Elsevier Business Intelligence

Roche has praised the flexibility of the UK’s Cancer Drugs Fund, but says NICE cost-effectiveness analysis would be unneces...

Original Article: UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary

NEXT ARTICLE

More From BioPortfolio on "UK Industry Rebates Could Make NICE Cost-Effectiveness Assessments Unnecessary"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...